Diabetes Action Canada will enhance patient-oriented research and contribute to improved patient outcomes by fostering alliances across and between research, policy, and practice by translating promising research findings into real-world demonstrable impacts.
OBJECTIVES OF THE NETWORK:
The main objectives of Diabetes Action Canada are to address the questions repeatedly articulated by Canadians living with diabetes: “what is my individual risk of developing blindness, kidney failure, lower limb amputation or heart failure?” and “what are the most effective ways to mitigate these risks?”
Keeping the end results in focus, our multi-disciplinary teams will bridge three major knowledge translation type 1 (KT1) gaps aligned with patients’ and healthcare providers’ priorities.
- Understand the accuracy of predictive rules about which individuals with Type 1 (T1D) or Type 2 (T2D) diabetes are at the highest risk for onset and progression of retinopathy (eye damage), neuropathy (nerve damage), nephropathy (kidney damage) and cardiovascular disease.
- Develop and apply user-friendly, customized diagnostic tools designed for both patients and healthcare providers to diagnose the risk of complications as early as possible based on sex, genomics, epigenetics, metabolomics, and by implementing new biological marker and organ imaging screening methods. Equally important are specific health determinants that modify the trajectory of diabetes complications including gender, lifestyle (diet and exercise) and co-morbidities (e.g., arthritis), and culturally appropriate care paths for those who are most vulnerable and at greatest risk.
- Evaluate new interventions based on technology and biomedical innovation, including lifestyle modifications targeted at preventing and reducing organ damage, new and repurposed drugs to reduce the onset and prevent progression of diabetes complications, and novel automated glycemic control devices, such as artificial pancreas and dual hormone insulin pumps. This KT1 gap will be bridged by conducting Phase 1 and 2 clinical trials ( the main focus of our Network), the results of which will inform the scale-up of larger, multi-centre Phase 3 and 4 clinical trials (KT2) and policy (KT3) necessary to ultimately transform healthcare.